http://www.fpnotebook.com/
Tazarotene
Aka: Tazarotene, Tazorac- Mechanism
- Retinoid
- Suppresses epidermal thickening, Scaling
- Dosing
- Applied each day
- Quick onset of benefit
- Start at 0.05% gel, may advance to 0.1% gel
- Efficacy
- Under 50% have moderate to marked benefit
- Best used in combination with topicals
- Benefit may last for several weeks after stopping
- Side Effects
- Erythema in almost everyone
- Not tolerated by 10% of patients
- Risk of Koebner Reaction
- Results in larger area Psoriasis
- Apply strictly to lesion
| Medication Costs | ||
|---|---|---|
| Tazorac (on 2/9/2012 at DrugStore.com) | ||
| Tazorac 0.1% Gel 30gm Tube | #1 for $250.98 | ($250.98/unit) |
| Tazorac 0.1% Gel 100gm Tube | #1 for $818.00 | ($818.00/unit) |
| Tazorac 0.05% Gel 30gm Tube | #1 for $209.98 | ($209.98/unit) |
| Tazorac 0.05% Gel 100gm Tube | #1 for $750.95 | ($750.95/unit) |
| Tazorac 0.05% Cream 30gm Tube | #1 for $209.98 | ($209.98/unit) |
| Tazorac 0.05% Cream 60gm Tube | #1 for $464.97 | ($464.97/unit) |
| Tazorac 0.1% Cream 30gm Tube | #1 for $245.98 | ($245.98/unit) |
| Tazorac 0.1% Cream 60gm Tube | #1 for $480.01 | ($480.01/unit) |
| FPNotebook does not benefit financially from showing this medication data or their pharmacy links. This information is provided only to help medical providers and their patients see relative costs. Insurance plans negotiate lower medication prices with suppliers. Prices shown here are out of pocket, non-negotiated rates. See Needy Meds for financial assistance information. | ||
tazarotene (C0288792) |
|
|---|---|
| Definition (NCI) | A drug used on the skin to treat several skin conditions. It is also being studied in the treatment of basal cell skin cancer and basal cell nevus syndrome. Avage is related to vitamin A and is made in the laboratory. It turns on a gene that may help stop the growth of skin cancer cells. Avage is a type of synthetic retinoid. |
| Definition (NCI) | A synthetic, topical retinoid. Tazarotene induces the expression of tazarotene-induced gene 3 (TIG3), a tumor suppressor gene. In psoriasis, tazarotene normalizes abnormal keratinocyte differentiation and reduces their hyperproliferation. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C086827 |
| SnomedCT | 332218002, 108906007, 386935009 |
| English | 3-Pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl)-, ethyl ester, ethyl 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinate, tazarotene, Ethyl 6-(2-(4,4-Dimethylthiochroman-6-yl)ethynyl)nicotinate, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl)ethynyl]- 3-Pyridinecarboxylic Acid, Ethyl Ester, retinoids tazarotene, tazarotene (medication), tazarotene [Chemical/Ingredient], TAZAROTENE, Tazarotene, Tazarotene (product), Tazarotene (substance) |
| Spanish | Tazarotene, tazaroteno (producto), tazaroteno (sustancia), tazaroteno |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |
Tazorac (C0723607) |
|
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C086827 |
| English | Tazorac, tazorac |
| Sources |
Derived from the NIH UMLS (Unified Medical Language System) |